



Supporting Information

© Wiley-VCH 2008

69451 Weinheim, Germany

Supporting Information

Highly Efficient and Selective Au(I)-Catalyzed Tandem Synthesis of Diversely Substituted Pyrrolo[1,2- α]quinolines in Aqueous Medium

Xin-Yuan Liu and Chi-Ming Che*

*Department of Chemistry and Open Laboratory of Chemical Biology, Institute of
Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong,
Pokfulam Road, Hong Kong (P. R. China)*


Table of Contents

Experimental Section	S2
Cytotoxicity Studies	S37
References	S38
Table S1	S39
Scheme S1	S40
Scheme S2	S41
Figure S1	S42
Spectra	S44

Experimental Section

General Methods. All manipulations with air-sensitive reagents were carried out under a dry argon atmosphere. Unless otherwise stated, all commercial reagents were used without additional purification. Solvents were dried using standard methods and distilled before use. The $\text{Au}(\text{PPh}_3)\text{Cl}$,^[S1] $(\text{IPr})\text{AuCl}$,^[S2] $\text{Au}[\text{P}(t\text{-Bu})_2(o\text{-biphenyl})]\text{Cl}$,^[S1,S3] $\text{Au}[\text{P}(\text{Cy})_2(2',4',6'\text{-triisopropyl-}o\text{-biphenyl})]\text{Cl}$,^[S1,S3] and $\text{Au}[\text{P}(t\text{-Bu})_2(2',4',6'\text{-triisopropyl-}o\text{-biphenyl})]\text{Cl}$ ^[S1,S3] catalysts were prepared following literature procedures. Analytical thin layer chromatography (TLC) was performed on precoated silica gel 60 F254 plates. Visualization on TLC was achieved by use of UV light (254 nm) or iodine. NMR spectra were recorded on a Bruker DPX-300/400 spectrometer at 300/400 MHz for ^1H NMR and 75/100 MHz for ^{13}C NMR in CDCl_3 with tetramethylsilane (TMS) as internal standard. The chemical shifts are expressed in ppm and coupling constants are given in Hz. Data for ^1H NMR are recorded as follows: chemical shift (ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quarter; m, multiplet), coupling constant (Hz), integration. Data for ^{13}C NMR are reported in terms of chemical shift (δ , ppm). IR spectra were recorded on a Bio-RAD PTS-165 spectrometer; frequencies are given in reciprocal centimeters (cm^{-1}) and only selected absorbance is reported. Mass spectra were determined on a Finnigan MAT 95 mass spectrometer.

Typical Experimental Procedures for the Syntheses of Aminoalkyne Substrates




To a solution of EDC·HCl (2.3 g, 12 mmol) and HOBr (1.5 g, 11.2 mmol) in CH₂Cl₂ (20 mL) was added a solution of 4-pentynoic acid (785 mg, 8 mmol) or 5-hexynoic acid (897 mg, 8 mmol) in CH₂Cl₂ (10 mL) followed by addition of a solution of amines (12 mmol) in CH₂Cl₂ (10 mL). The mixture was cooled to 0 °C and Et₃N (1.2 mL, 12 mmol) was added dropwise. After being slowly warmed to room temperature and stirred overnight, the reaction mixture was diluted with CH₂Cl₂, washed successively with water, aqueous HCl 5%, saturated NaHCO₃, and brine, and dried over Na₂SO₄. Evaporation of the solvent followed by column chromatography on silica gel with EtOAc/Hx (1:2) as eluent afforded substituted 4-pentynoylamine or 5-hexynoylamine in good to excellent yields.

To a solution of substituted 4-pentynoylamine or 5-hexynoylamine (4 mmol) in THF (30 mL) was slowly added lithium aluminum hydride (642 mg, 16 mmol) at 0 °C. The reaction mixture was slowly warmed to room temperature and stirred for 24–30 h, and then quenched with Baechströms reagent (Na₂SO₄·10H₂O) and stirred for 30 min. After filtration, the filtrate was evaporated and chromatographed on silica gel column with EtOAc/Hx (1:20) as eluent to afford substituted aminoalkynes in good to excellent yields.


N-(4-methoxyphenyl)pent-4-ynamide^[S4] and **N-benzylpent-4-yn-1-amine (1K)**^[S5] were prepared following literature procedures.

4-Methoxy-N-(pent-4-ynyl)aniline (1A):




¹H NMR (CDCl₃, TMS, 400 MHz): δ 6.83 (m, 2H), 6.63 (m, 2H), 3.78 (s, 3H), 3.52 (br, 1H), 3.23 (t, J = 6.8 Hz, 2H), 2.34 (m, 2H), 2.06 (t, J = 2.6 Hz, 1H), 1.85 (m, 2H). ¹³C NMR (CDCl₃, TMS, 100 MHz): δ 152.0, 142.5, 114.9, 114.1, 83.9, 69.1, 55.8, 43.7, 28.1, 16.2. IR (film): ν 3305, 3056, 2950, 1603, 1509 cm⁻¹. MS: *m/z* (% relative intensity) 189(M⁺, 69), 188(17), 174(9), 136(100); HRMS: *m/z* calcd for C₁₂H₁₅NO (M⁺) 189.1154, found 189.1145.

N-(4-phenoxyphenyl)pent-4-ynamide:



¹H NMR (CDCl₃, TMS, 300 MHz): δ 8.26 (s, 1H), 7.48 (d, J = 8.7 Hz, 2H), 7.31 (t, J = 7.8 Hz, 2H), 7.08 (t, J = 7.3 Hz, 1H), 6.96 (m, 4H), 2.59 (s, 4H), 2.04 (s, 1H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 169.8, 157.4, 153.6, 133.3, 129.8, 123.2, 122.2, 119.5, 118.5, 82.8, 69.7, 36.0, 14.9. IR (film): ν 3434, 3304, 3056, 1684, 1590, 1509 cm⁻¹. MS: *m/z* (% relative intensity) 265(M⁺, 61), 186(12), 185(100), 108(29); HRMS: *m/z* calcd for C₁₇H₁₅NO₂ (M⁺) 265.1103, found 265.1105.


N-(pent-4-ynyl)-4-phenoxyaniline (1B):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.34 (m, 2H), 7.02 (m, 5H), 6.66 (m, 2H), 3.72 (br, 1H), 3.29 (t, J = 6.8 Hz, 2H), 2.37 (m, 2H), 2.08 (t, J = 2.6 Hz, 1H), 1.88 (m, 2H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 159.2, 147.6, 144.9, 129.6, 122.0, 121.4, 117.1, 113.8, 83.8, 69.2, 43.4, 28.1, 16.2. IR (film): ν 3299, 3056, 1597, 1509, 1484 cm⁻¹. MS: *m/z* (%


relative intensity) 251(M^+ , 100), 250(23), 198(100), 157(11); HRMS: m/z calcd for $C_{17}H_{17}NO$ (M^+) 251.1310, found 251.1308.

***N*-(2-methoxyphenyl)pent-4-ynamide:**




1H NMR ($CDCl_3$, TMS, 300 MHz): δ 8.31 (d, $J = 7.0$ Hz, 1H), 7.96 (s, 1H), 6.89 (m, 3H), 3.77 (s, 3H), 2.53 (s, 4H), 2.02 (s, 1H). ^{13}C NMR ($CDCl_3$, TMS, 75 MHz): δ 169.0, 147.9, 127.5, 123.8, 120.9, 119.9, 110.0, 82.9, 69.5, 55.6, 36.4, 14.7. IR (film): ν 3421, 3305, 2842, 1684, 1603, 1522, 1484 cm^{-1} . MS: m/z (% relative intensity) 203(M^+ , 66), 123(100), 108(37); HRMS: m/z calcd for $C_{12}H_{13}NO_2$ (M^+) 203.0946, found 203.0939.

2-Methoxy-*N*-(pent-4-ynyl)aniline (1C):




1H NMR ($CDCl_3$, TMS, 300 MHz): δ 7.03 (m, 1H), 6.89 (m, 1H), 6.80 (m, 2H), 4.42 (br, 1H), 3.94 (s, 3H), 3.39 (t, $J = 6.9$ Hz, 2H), 2.43 (m, 2H), 2.14 (t, $J = 2.6$ Hz, 1H), 1.97 (m, 2H). ^{13}C NMR ($CDCl_3$, TMS, 75 MHz): δ 146.9, 138.3, 121.5, 116.5, 109.8, 109.6, 83.9, 69.2, 55.5, 42.5, 28.3, 16.3. IR (film): ν 3305, 2950, 1597, 1516, 1354 cm^{-1} . MS: m/z (% relative intensity) 189(M^+ , 21), 153(55), 136(53), 77(100); HRMS: m/z calcd for $C_{12}H_{15}NO$ (M^+) 189.1154, found 189.1159.

***N*-p-tolylpent-4-ynamide:**




¹H NMR (CDCl₃, TMS, 300 MHz): δ 8.00 (s, 1H), 7.39 (d, J = 8.3 Hz, 2H), 7.09 (d, J = 8.1 Hz, 2H), 2.56 (s, 4H), 2.30 (s, 3H), 2.03 (s, 1H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 169.5, 135.2, 134.0, 129.4, 120.3, 82.9, 69.6, 36.1, 20.8, 14.8. IR (film): ν 3426, 3305, 3064, 2988, 1684, 1603, 1516 cm⁻¹. MS: *m/z* (% relative intensity) 187(M⁺, 30), 153(15), 107(100), 106(34); HRMS: *m/z* calcd for C₁₂H₁₃NO (M⁺) 187.0997, found 187.0999.

4-Methyl-N-(pent-4-ynyl)aniline (1D):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.13 (d, J = 8.0 Hz, 2H), 6.67 (d, J = 8.4 Hz, 2H), 3.68 (br, 1H), 3.34 (t, J = 6.8 Hz, 2H), 2.43 (m, 2H), 2.39 (s, 3H), 2.14 (t, J = 2.7 Hz, 1H), 1.92 (m, 2H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 146.1, 129.9, 126.5, 113.1, 84.0, 69.2, 43.2, 28.2, 20.5, 16.3. IR (film): ν 3305, 3056, 2988, 1611, 1509, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 173(M⁺, 39), 172(15), 120(100); HRMS: *m/z* calcd for C₁₂H₁₅N (M⁺) 173.1204, found 173.1197.


***N*-(4-chlorophenyl)pent-4-ynamide:**



¹H NMR (CDCl₃, TMS, 300 MHz): δ 9.33 (s, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.29 (d, J = 8.8 Hz, 2H), 2.57 (m, 4H), 2.35 (s, 1H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 205.6, 169.4, 138.1, 128.6, 120.7, 83.0, 69.5, 35.7, 14.1. IR (film): ν 3421, 3299, 3050, 1692,


1590, 1509 cm⁻¹. MS: *m/z* (% relative intensity) 209(M⁺+2, 8), 207(M⁺, 24), 129(30), 127(100); HRMS: *m/z* calcd for C₁₁H₁₀NOCl (M⁺) 207.0451, found 207.0449.

4-Chloro-N-(pent-4-ynyl)aniline (1E):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.14 (d, *J* = 8.8 Hz, 2H), 6.53 (d, *J* = 8.8 Hz, 2H), 3.78 (br, 1H), 3.22 (t, *J* = 6.8 Hz, 2H), 2.32 (m, 2H), 2.09 (t, *J* = 2.6 Hz, 1H), 1.83 (m, 2H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 146.9, 129.1, 121.6, 113.9, 83.8, 69.4, 42.9, 27.9, 16.2. IR (film): ν 3305, 3064, 2983, 1603, 1495, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 195(M⁺+2, 12), 193(M⁺, 34), 142(32), 140(100); HRMS: *m/z* calcd for C₁₁H₁₂NCI (M⁺) 193.0658, found 193.0653.

N-(2-Fluorophenyl)pent-4-ynamide:




¹H NMR (CDCl₃, TMS, 400 MHz): δ 8.13 (m, 2H), 7.01 (m, 3H), 2.56 (m, 4H), 2.05 (s, 1H). ¹³C NMR (CDCl₃, TMS, 100 MHz): δ 169.9, 154.1, 151.7, 124.7 (d, *J*_{CF} = 7.5 Hz), 124.4, 124.3, 122.6, 114.9 (d, *J*_{CF} = 19.1 Hz), 82.7, 69.7, 36.0, 14.6. IR (film): ν 3434, 3305, 1698, 1617, 1522, 1457 cm⁻¹. MS: *m/z* (% relative intensity) 191(M⁺, 17), 112(7), 111(100); HRMS: *m/z* calcd for C₁₁H₁₀FNO (M⁺) 191.0746, found 191.0752.

2-Fluoro-N-(pent-4-ynyl)aniline (1F):




¹H NMR (CDCl₃, TMS, 400 MHz): δ 7.02 (m, 2H), 6.77 (m, 1H), 6.68 (m, 1H), 4.04 (br, 1H), 3.34 (s, 2H), 2.37 (m, 2H), 2.07 (t, $J = 2.7$ Hz, 1H), 1.89 (m, 2H). ¹³C NMR (CDCl₃, TMS, 100 MHz): δ 152.8, 150.4, 136.6 (d, $J_{CF} = 11.4$ Hz), 124.6 (d, $J_{CF} = 3.5$ Hz), 116.5 (d, $J_{CF} = 6.9$ Hz), 114.4 (d, $J_{CF} = 18.4$ Hz), 111.9 (d, $J_{CF} = 3.3$ Hz), 83.5, 69.2, 42.3, 28.0, 16.0. IR (film): ν 3305, 2950, 1617, 1516, 1335 cm⁻¹. MS: *m/z* (% relative intensity) 177(M⁺, 27), 153(8), 124(100); HRMS: *m/z* calcd for C₁₁H₁₂FN (M⁺) 177.0954, found 177.0946.

***N*-(naphthalen-1-yl)pent-4-ynamide:**



¹H NMR (CDCl₃, TMS, 300 MHz): δ 8.15 (s, 1H), 7.84 (t, $J = 9.8$ Hz, 2H), 7.74 (d, $J = 7.4$ Hz, 1H), 7.65 (d, $J = 8.2$ Hz, 1H), 7.40 (m, 3H), 2.62 (m, 4H), 2.10 (s, 1H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 170.3, 134.0, 132.2, 128.6, 127.6, 126.2, 126.1, 125.9, 125.6, 121.6, 121.2, 83.1, 69.8, 36.0, 15.0. IR (film): ν 3426, 3305, 3042, 2929, 1684, 1522, 1495 cm⁻¹. MS: *m/z* (% relative intensity) 223(M⁺, 19), 153(82), 143(70), 77(100); HRMS: *m/z* calcd for C₁₅H₁₃NO (M⁺) 223.0997, found 223.0997.


***N*-(pent-4-ynyl)naphthalene-1-amine (**1G**):**



¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.96 (d, $J = 7.6$ Hz, 1H), 7.89 (d, $J = 8.1$ Hz, 1H), 7.56 (m, 3H), 7.42 (d, $J = 8.1$ Hz, 1H), 6.75 (d, $J = 7.4$ Hz, 1H), 4.53 (br, 1H), 3.47 (t, $J = 6.8$ Hz, 2H), 2.47 (m, 2H), 2.24 (t, $J = 2.6$ Hz, 1H), 2.03 (m, 2H). ¹³C NMR (CDCl₃,


TMS, 75 MHz): δ 143.5, 134.5, 128.8, 126.9, 125.9, 124.8, 123.6, 120.1, 117.5, 104.4, 84.2, 69.5, 43.3, 27.9, 16.6. IR (film): ν 3305, 3064, 2988, 1576, 1522, 1484 cm^{-1} . MS: m/z (% relative intensity) 209(M^+ , 96), 208(51), 156(100), 129(42); HRMS: m/z calcd for $C_{15}\text{H}_{15}\text{N}$ (M^+) 209.1204, found 209.1197.

N-(4-methoxyphenyl)hex-5-ynamide:




^1H NMR (CDCl_3 , TMS, 300 MHz): δ 7.86 (br, 1H), 7.38 (d, $J = 8.9$ Hz, 2H), 6.80 (d, $J = 8.9$ Hz, 2H), 3.75 (s, 3H), 2.44 (t, $J = 7.3$ Hz, 2H), 2.26 (m, 2H), 1.99 (t, $J = 2.6$ Hz, 1H), 1.90 (m, 2H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 170.8, 156.4, 131.0, 122.0, 114.0, 83.5, 69.3, 55.4, 35.7, 24.1, 17.9. IR (film): ν 3426, 3305, 3056, 1684, 1590, 1509, 1408 cm^{-1} . MS: m/z (% relative intensity) 217(M^+ , 31), 153(21), 123(100), 108(61); HRMS: m/z calcd for $C_{13}\text{H}_{15}\text{NO}_2$ (M^+) 217.1103, found 217.1102.

N-(hex-5-ynyl)-4-methoxyaniline (1J):



^1H NMR (CDCl_3 , TMS, 300 MHz): δ 6.82 (m, 2H), 6.59 (m, 2H), 3.76 (s, 3H), 3.39 (br, 1H), 3.09 (t, $J = 6.7$ Hz, 2H), 2.26 (m, 2H), 2.06 (t, $J = 2.6$ Hz, 1H), 1.69 (m, 4H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 152.0, 142.8, 114.9, 114.0, 84.3, 68.9, 55.7, 44.4, 28.7, 26.1, 18.3. IR (film): ν 3303, 3052, 2934, 2864, 1707, 1507 cm^{-1} . MS: m/z (% relative intensity) 203(M^+ , 47), 202(14), 136(100); HRMS: m/z calcd for $C_{13}\text{H}_{17}\text{NO}$ (M^+) 203.1310, found 203.1297.




To a solution of diisopropylamine (1821 mg, 18 mmol) in THF (25 mL) was added dropwise *n*BuLi (7.2 mL, 2.5 M solution in hexanes) at 0 °C under Ar atmosphere. The resulting solution was stirred for 30 min before cooling to -78 °C. To this freshly prepared LDA solution, a solution of cyanocyclohexane (1635 mg, 15 mmol) was added dropwise at -78 °C and stirred for 1 h at -78 °C followed by the addition of propargyl bromide (1840 µL, 80 wt% solution in toluene). The reaction mixture was stirred for 1 h at -78 °C and then warmed to room temperature. Saturated aq NH₄Cl (30 mL) was added, followed by addition of diethyl ether (60 mL) and extraction with diethyl ether (60 mL × 3). The organic layer was dried (Na₂SO₄), filtered, evaporated, and purified by a silica gel chromatography (EtOAc/Hx, 1:50) to afford propargylated cyclohexanenitrile (1.98 g).^[S5]

To a solution of the above obtained nitrile (441 mg, 3 mmol) in diethyl ether (30 mL) was added dropwise diisobutylaluminum hydride (6 mL, 1.0 M solution in toluene) under Ar atmosphere at -78 °C. After stirring for 5 h at -30 to -78 °C, MeOH (6 mL) was added, followed by addition of aromatic amines (4.5 mmol). The reaction mixture was warmed to room temperature and heated at 60 °C for 8 h. Rubber septum was removed and sodium borohydride (378 mg, 15 mmol) was added. The reaction mixture was stirred overnight at room temperature. The organic solvent was removed under reduced pressure and the residue was re-dissolved in dichloromethane (60 mL). The resulting slurry was washed with saturated aqueous sodium bicarbonate solution, water and brine. The organic layer was dried over anhydrous Na₂SO₄ and filtered. The solvent was removed and the


residue was purified by a silica gel column chromatography (EtOAc/Hx, 1:40) to give the desired product in good yield.^[S5]

4-Methoxy-N-((1-(prop-2-ynyl)cyclohexyl)methyl)aniline (1H):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 6.82 (m, 2H), 6.68 (m, 2H), 3.77 (s, 3H), 3.51 (br, 1H), 3.12 (s, 2H), 2.34 (d, J = 2.6 Hz, 2H), 2.08 (t, J = 2.7 Hz, 1H), 1.51 (m, 10H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 151.9, 143.5, 114.9, 114.3, 82.0, 70.7, 55.8, 52.5, 37.0, 33.4, 26.1, 25.8, 21.7. IR (film): ν 3070, 2929, 2855, 1603, 1509 cm⁻¹. MS: *m/z* (% relative intensity) 257(M⁺, 100), 256(100), 214(70), 201(43); HRMS: *m/z* calcd for C₁₇H₂₃NO (M⁺) 257.1780, found 257.1770.

4-Phenoxy-N-((1-(prop-2-ynyl)cyclohexyl)methyl)aniline (1I):




¹H NMR (CDCl₃, TMS, 400 MHz): δ 7.37 (m, 2H), 7.05 (m, 5H), 6.76 (d, J = 8.9 Hz, 2H), 3.79 (br, 1H), 3.22 (s, 2H), 2.41 (d, J = 2.7 Hz, 2H), 2.16 (t, J = 2.7 Hz, 1H), 1.57 (m, 10H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 159.3, 147.4, 146.0, 129.6, 122.0, 121.4, 117.1, 114.0, 82.0, 71.0, 52.2, 37.1, 33.4, 26.2, 25.9, 21.8. IR (film): ν 2929, 2848, 1603, 1516, 1484 cm⁻¹. MS: *m/z* (% relative intensity) 319(M⁺, 100), 318(67), 262(53), 153(58); HRMS: *m/z* calcd for C₂₂H₂₅NO (M⁺) 319.1936, found 319.1927.

General Procedure for Au(I)-Catalyzed Tandem Synthesis of Diversely Substituted Pyrrolo[1,2- α]quinolines in Water


A mixture of Au[P(*t*-Bu)₂(*o*-biphenyl)]Cl (0.005 or 0.002 mmol), AgSbF₆ (0.005 or 0.002 mmol), alkyne (0.4 or 0.3 mmol) and 1,4-aminoalkyne (0.1 mmol) in water (0.4 mL) was stirred at 75 °C for 24–45 h under Ar atmosphere. Water was removed under reduced pressure, and the residue was purified by a silica gel column chromatography (EtOAc/Hx, 1:100) to give the desired product.

7-Methoxy-3a-methyl-5-phenyl-1,2,3,3a-tetrahydropyrrolo[1,2- α]quinoline (3Aa):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.37 (m, 5H), 6.77 (dd, *J* = 8.6, 2.9 Hz, 1H), 6.61 (d, *J* = 2.8 Hz, 1H), 6.47 (d, *J* = 7.5 Hz, 1H), 5.73 (s, 1H), 3.67 (s, 3H), 3.42 (m, 2H), 2.05 (m, 4H), 1.13 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 150.7, 139.9, 138.3, 135.8, 129.3, 129.1, 128.2, 127.3, 123.4, 114.1, 112.9, 112.8, 60.9, 55.9, 45.9, 38.0, 22.6, 20.7. IR (film): ν 2969, 2834, 1603, 1563, 1489, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 291(M⁺, 1), 277(12), 276(100), 153(42); HRMS: *m/z* calcd for C₂₀H₂₁NO (M⁺) 291.1623, found 291.1615.

7-Methoxy-3a-methyl-5-*p*-tolyl-1,2,3,3a-tetrahydropyrrolo[1,2- α]quinoline (3Ab):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.26 (d, *J* = 8.0 Hz, 2H), 7.19 (d, *J* = 8.0 Hz, 2H), 6.76 (dd, *J* = 8.6, 2.9 Hz, 1H), 6.63 (d, *J* = 2.5 Hz, 1H), 6.48 (s, 1H), 5.71 (s, 1H), 3.67 (s, 3H), 3.43 (s, 2H), 2.40 (s, 3H), 2.03 (m, 4H), 1.11 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 150.7, 138.2, 137.0, 136.9, 135.6, 129.1, 129.0, 128.8, 123.5, 114.1, 112.9, 112.8, 60.9, 55.9, 45.8, 38.0, 22.5, 21.2, 20.7. IR (film): ν 2961, 2927, 1491, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 305(M⁺, 4), 291(20), 290(100), 247(10); HRMS: *m/z* calcd for C₂₁H₂₃NO (M⁺) 305.1780, found 305.1782.

7-Methoxy-5-(4-methoxyphenyl)-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Ac):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.28 (m, 2H), 6.92 (m, 2H), 6.75 (dd, *J* = 8.6, 2.9 Hz, 1H), 6.61 (d, *J* = 2.8 Hz, 1H), 6.45 (d, *J* = 8.5 Hz, 1H), 5.68 (s, 1H), 3.85 (s, 3H), 3.66 (s, 3H), 3.41 (m, 2H), 2.02 (m, 4H), 1.09 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 158.9, 150.7, 138.3, 135.2, 132.3, 130.2, 128.9, 123.6, 114.1, 113.6, 112.8, 112.7, 60.8, 55.9, 55.3, 45.8, 38.0, 22.4, 20.7. IR (film): ν 2963, 2842, 1603, 1503, 1416 cm⁻¹. MS: *m/z* (% relative intensity) 321(M⁺, 5), 307(16), 306(100), 153(33); HRMS: *m/z* calcd for

$C_{21}H_{23}NO_2(M^+)$ 321.1729, found 321.1726.

7-Methoxy-5-(3-methoxyphenyl)-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-


a]quinoline (3Ad):



1H NMR ($CDCl_3$, TMS, 400 MHz): δ 7.27 (d, $J = 7.6$ Hz, 1H), 6.93 (d, $J = 7.6$ Hz, 1H), 6.88 (m, 2H), 6.74 (dd, $J = 8.6, 2.9$ Hz, 1H), 6.60 (d, $J = 2.8$ Hz, 1H), 6.44 (d, $J = 8.6$ Hz, 1H), 5.70 (s, 1H), 3.81 (s, 3H), 3.65 (s, 3H), 3.40 (m, 2H), 2.01 (m, 4H), 1.09 (s, 3H). ^{13}C NMR ($CDCl_3$, TMS, 100 MHz): δ 159.4, 150.7, 141.4, 138.2, 135.6, 129.2, 129.1, 123.2, 121.6, 114.5, 114.3, 113.0, 112.8, 112.7, 60.8, 55.9, 55.2, 45.8, 38.0, 22.6, 20.7. IR (film): ν 2963, 2834, 1603, 1484, 1457, 1282 cm^{-1} . MS: m/z (% relative intensity) 321(M^+ , 5), 307(18), 306(100), 153(52); HRMS: m/z calcd for $C_{21}H_{23}NO_2(M^+)$ 321.1729, found 321.1733.

7-Methoxy-5-(2-methoxyphenyl)-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-


a]quinoline (3Ae):



1H NMR ($CDCl_3$, TMS, 300 MHz): δ 7.30 (m, 1H), 7.16 (br, 1H), 6.95 (m, 2H), 6.68 (dd, $J = 8.6, 2.9$ Hz, 1H), 6.39 (d, $J = 8.6$ Hz, 1H), 6.28 (d, $J = 2.4$ Hz, 1H), 5.66 (s, 1H), 3.71


(s, 3H), 3.60 (s, 3H), 3.41 (m, 2H), 2.00 (m, 4H), 1.12 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 157.5, 150.7, 137.9, 131.4, 130.0, 128.9, 128.7, 123.5, 120.6, 113.6, 112.8, 112.3, 111.2, 61.1, 55.9, 55.7, 46.1, 38.0, 23.2, 20.6. IR (film): ν 2963, 2929, 2842, 1597, 1495, 1457, 1416 cm^{-1} . MS: m/z (% relative intensity) 321(M^+ , 4), 307(23), 306(100), 153(24); HRMS: m/z calcd for $\text{C}_{21}\text{H}_{23}\text{NO}_2(\text{M}^+)$ 321.1729, found 321.1735.

5-(Biphenyl-4-yl)-7-methoxy-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Af):




^1H NMR (CDCl_3 , TMS, 300 MHz): δ 7.63 (m, 4H), 7.45 (m, 5H), 6.78 (dd, $J = 8.6, 2.9$ Hz, 1H), 6.66 (d, $J = 2.9$ Hz, 1H), 6.47 (d, $J = 8.6$ Hz, 1H), 5.77 (s, 1H), 3.67 (s, 3H), 3.44 (m, 2H), 2.04 (m, 4H), 1.12 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 150.7, 140.9, 140.1, 139.0, 138.3, 135.4, 129.5, 129.4, 128.8, 127.2, 127.1, 126.9, 123.2, 114.2, 112.9, 112.8, 60.9, 56.0, 45.8, 38.0, 22.6, 20.7. IR (film): ν 2961, 1603, 1491, 1422 cm^{-1} . MS: m/z (% relative intensity) 367(M^+ , 3), 353(19), 352(67), 149(100); HRMS: m/z calcd for $\text{C}_{26}\text{H}_{25}\text{NO}(\text{M}^+)$ 367.1936, found 367.1940.

7-Methoxy-3a-methyl-5-(4-(trifluoromethyl)phenyl)-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Ag):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.63 (d, *J* = 7.8 Hz, 2H), 7.46 (d, *J* = 7.7 Hz, 2H), 6.76 (dd, *J* = 8.6, 2.6 Hz, 1H), 6.48 (s, 1H), 6.47 (d, *J* = 8.2 Hz, 1H), 5.71 (s, 1H), 3.66 (s, 3H), 3.41 (m, 2H), 2.06 (m, 4H), 1.11 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 150.7, 143.8, 138.2, 134.8, 130.1, 129.4, 127.7, 126.3, 125.1 (m, CF₃), 122.6, 114.4, 113.0, 112.6, 60.9, 55.9, 45.8, 38.0, 22.6, 20.7. IR (film): ν 3064, 2983, 2842, 1603, 1563, 1489, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 359(M⁺, 7), 345(21), 344(100), 301(10); HRMS: *m/z* calcd for C₂₁H₂₀NOF₃(M⁺) 359.1497, found 359.1493.


5-(4-Fluorophenyl)-7-methoxy-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Ah):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.30 (m, 2H), 7.06 (m, 2H), 6.75 (dd, *J* = 8.6, 2.9 Hz, 1H), 6.52 (d, *J* = 2.9 Hz, 1H), 6.45 (d, *J* = 8.6 Hz, 1H), 5.68 (s, 1H), 3.66 (s, 3H), 3.40 (m, 2H), 2.02 (m, 4H), 1.09 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 163.8, 160.6, 150.7, 138.2, 135.9 (d, *J*_{CF} = 3.3 Hz), 134.8, 130.7 (d, *J*_{CF} = 7.8 Hz), 129.4, 123.2, 115.1, 114.9, 114.2, 112.8 (d, *J*_{CF} = 6.5 Hz), 60.8, 55.9, 45.8, 38.0, 22.5, 20.7. IR (film): ν 2969, 2844, 1603, 1499, 1498 cm⁻¹. MS: *m/z* (% relative intensity) 309(M⁺, 4), 295(14),


294(100), 251(19); HRMS: *m/z* calcd for C₂₀H₂₀NOF (M⁺) 309.1529, found 309.1525.

5-Cyclohexenyl-7-methoxy-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Ai):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 6.69 (m, 2H), 6.37 (m, 1H), 5.69 (s, 1H), 5.55 (s, 1H), 3.74 (s, 3H), 3.33 (m, 2H), 2.07 (m, 8H), 1.65 (m, 4H), 0.98 (s, 3H). ¹³C NMR (CDCl₃, TMS, 100 MHz): δ 150.7, 138.2, 137.8, 137.1, 126.9, 126.2, 123.0, 113.3, 112.4, 60.6, 55.9, 45.6, 37.9, 29.1, 25.4, 23.0, 22.3, 22.2, 20.6. IR (film): ν 2942, 2848, 1611, 1489, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 295(M⁺, 5), 281(20), 280(100), 153(7); HRMS: *m/z* calcd for C₂₀H₂₅NO (M⁺) 295.1936, found 295.1940.


5-Butyl-7-methoxy-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Aj):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 6.80 (d, *J* = 2.8 Hz, 1H), 6.71 (dd, *J* = 8.5, 2.8 Hz, 1H), 6.37 (d, *J* = 8.6 Hz, 1H), 5.56 (s, 1H), 3.79 (s, 3H), 3.36 (m, 2H), 2.37 (m, 2H), 1.94 (m, 4H), 1.54 (m, 2H), 1.41 (m, 2H), 1.02 (s, 3H), 0.94 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 150.8, 138.2, 132.3, 127.1, 123.4, 113.1, 112.3, 110.7, 60.6, 56.0, 46.1, 38.2, 31.8, 30.6, 23.3, 22.7, 20.6, 14.0. IR (film): ν 3064, 2988, 2963, 2929,


1603, 1563, 1495 cm^{-1} . MS: m/z (% relative intensity) 271(M^+ , 7), 257(20), 256(100); HRMS: m/z calcd for $\text{C}_{18}\text{H}_{25}\text{NO} (\text{M}^+)$ 271.1936, found 271.1935.

3a-Methyl-7-phenoxy-5-p-tolyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Bb):



^1H NMR (CDCl_3 , TMS, 300 MHz): δ 7.22 (m, 6H), 6.92 (m, 4H), 6.79 (d, $J = 2.7$ Hz, 1H), 6.47 (d, $J = 8.5$ Hz, 1H), 5.69 (s, 1H), 3.48 (m, 2H), 2.37 (s, 3H), 2.06 (m, 4H), 1.17 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 159.5, 145.6, 140.5, 137.0, 136.7, 135.4, 129.4, 129.0, 128.9, 128.5, 123.3, 121.5, 120.9, 119.0, 116.5, 112.4, 61.1, 45.6, 38.1, 23.1, 21.1, 20.6. IR (film): ν 3056, 2983, 2929, 1597, 1484, 1422 cm^{-1} . MS: m/z (% relative intensity) 367(M^+ , 3), 353(25), 352(100); HRMS: m/z calcd for $\text{C}_{26}\text{H}_{25}\text{NO} (\text{M}^+)$ 367.1936, found 367.1938.

5-(4-Methoxyphenyl)-3a-methyl-7-phenoxy-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Bc):




^1H NMR (CDCl_3 , TMS, 300 MHz): δ 7.25 (m, 4H), 6.90 (m, 6H), 6.77 (d, $J = 2.7$ Hz, 1H), 6.47 (d, $J = 8.5$ Hz, 1H), 5.68 (s, 1H), 3.82 (s, 3H), 3.47 (m, 2H), 2.04 (m, 4H), 1.16 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 159.4, 159.0, 145.7, 140.5, 135.0, 132.0,

130.1, 129.4, 128.3, 123.4, 121.5, 120.9, 118.9, 116.5, 113.6, 112.4, 61.1, 55.3, 45.6, 38.1, 23.1, 20.7. IR (film): ν 3056, 2963, 2848, 1603, 1516, 1484, 1430 cm^{-1} . MS: m/z (%) relative intensity) 383(M^+ , 4), 369(30), 368(100), 352(33); HRMS: m/z calcd for $C_{26}H_{25}NO_2(M^+)$ 383.1885, found 383.1884.

5-(3-Methoxyphenyl)-3a-methyl-7-phenoxy-1,2,3,3a-tetrahydropyrrolo[1,2-


a]quinoline (3Bd):



^1H NMR (CDCl_3 , TMS, 400 MHz): δ 7.21 (m, 3H), 6.87 (m, 7H), 6.76 (d, $J = 2.7$ Hz, 1H), 6.45 (d, $J = 8.6$ Hz, 1H), 5.70 (s, 1H), 3.75 (s, 3H), 3.45 (m, 2H), 2.04 (m, 4H), 1.14 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 100 MHz): δ 159.4, 145.7, 141.1, 140.4, 135.4, 129.3, 129.2, 128.7, 123.0, 121.5, 121.4, 121.0, 118.9, 116.5, 114.4, 113.2, 112.5, 61.1, 55.2, 45.6, 38.1, 23.1, 20.5. IR (film): ν 2969, 2842, 1597, 1484, 1430, 1287 cm^{-1} . MS: m/z (%) relative intensity) 383(M^+ , 2), 369(25), 368(100), 153(26); HRMS: m/z calcd for $C_{26}H_{25}NO_2(M^+)$ 383.1885, found 383.1889.


5-(2-Methoxyphenyl)-3a-methyl-7-phenoxy-1,2,3,3a-tetrahydropyrrolo[1,2-

a]quinoline (3Be):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.22 (m, 4H), 6.86 (m, 6H), 6.40 (m, 2H), 5.67 (s, 1H), 3.68 (s, 3H), 3.46 (m, 2H), 2.10 (m, 4H), 1.17 (s, 3H). ¹³C NMR (CDCl₃, TMS, 100 MHz): δ 159.6, 157.0, 145.5, 140.0, 131.6, 130.9, 129.5, 129.2, 129.0, 128.9, 128.5, 123.1, 121.3, 120.6, 118.9, 116.4, 112.0, 110.8, 61.3, 55.5, 45.5, 38.0, 23.2, 20.4. IR (film): ν 3056, 2983, 2842, 1603, 1489, 1422, 1281 cm⁻¹. MS: *m/z* (% relative intensity) 383(M⁺, 4), 369(28), 368(100), 352(37); HRMS: *m/z* calcd for C₂₆H₂₅NO₂(M⁺) 383.1885, found 383.1889.

5-Cyclohexenyl-3a-methyl-7-phenoxy-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Bi):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.26 (m, 2H), 6.96 (m, 3H), 6.79 (m, 2H), 6.38 (dd, *J* = 9.0, 1.7 Hz, 1H), 5.66 (m, 1H), 5.54 (s, 1H), 3.38 (m, 2H), 2.03 (m, 8H), 1.62 (m, 4H), 1.03 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 159.3, 146.0, 140.3, 137.7, 136.9, 129.4, 126.4, 126.3, 122.7, 121.6, 120.2, 118.0, 116.8, 112.3, 60.8, 45.4, 38.0, 29.1, 25.3, 22.9, 22.2, 20.5. IR (film): ν 3056, 2983, 2929, 2855, 1611, 1570, 1484, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 357(M⁺, 3), 343(28), 342(100), 153(22); HRMS: *m/z* calcd for C₂₅H₂₇NO (M⁺) 357.2093, found 357.2093.

5-Butyl-3a-methyl-7-phenoxy-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Bj):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.27 (m, 2H), 6.94 (m, 4H), 6.80 (dd, J = 8.5, 2.7 Hz, 1H), 6.36 (d, J = 8.6 Hz, 1H), 5.54 (s, 1H), 3.39 (m, 2H), 2.30 (m, 2H), 2.01 (m, 4H), 1.50 (m, 2H), 1.32 (m, 2H), 1.04 (s, 3H), 0.89 (t, J = 7.2 Hz, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 159.5, 145.8, 140.3, 132.2, 129.4, 126.5, 123.2, 121.5, 120.3, 116.7, 116.3, 112.1, 60.9, 45.8, 38.3, 31.7, 30.5, 23.8, 22.6, 20.4, 14.0. IR (film): ν 2963, 2929, 2869, 1597, 1563, 1484, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 333(M⁺, 4), 319(25), 318(100), 274(21); HRMS: *m/z* calcd for C₂₃H₂₇NO (M⁺) 333.2093, found 333.2092.

9-Methoxy-5-(4-methoxyphenyl)-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3C_c):



¹H NMR (CDCl₃, TMS, 400 MHz): δ 7.25 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 8.3 Hz, 2H), 6.75 (m, 3H), 5.48 (s, 1H), 3.93 (m, 1H), 3.89 (s, 3H), 3.83 (s, 3H), 3.11 (m, 1H), 2.03 (m, 2H), 1.90 (m, 1H), 1.66 (m, 1H), 1.20 (s, 3H). ¹³C NMR (CDCl₃, TMS, 100 MHz): δ 158.8, 152.1, 135.3, 134.5, 132.8, 130.3, 130.0, 126.4, 119.4, 119.0, 113.4, 110.8, 60.7, 55.8, 55.3, 54.3, 40.4, 27.4, 24.9. IR (film): ν 2969, 2848, 1603, 1503, 1457, 1349 cm⁻¹. MS: *m/z* (% relative intensity) 321(M⁺, 5), 307(17), 306(100), 153(30); HRMS: *m/z* calcd for C₂₁H₂₃NO₂ (M⁺) 321.1729, found 321.1742.


3a,7-Dimethyl-5-p-tolyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Db):



3Db

¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.23 (m, 4H), 6.94 (dd, *J* = 8.0, 1.5 Hz, 1H), 6.78 (d, *J* = 1.6 Hz, 1H), 6.42 (d, *J* = 8.0 Hz, 1H), 5.63 (s, 1H), 3.45 (m, 2H), 2.41 (s, 3H), 2.16 (s, 3H), 2.02 (m, 4H), 1.12 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 141.3, 137.4, 136.7, 135.7, 129.2, 129.1, 128.8, 128.0, 126.8, 124.4, 122.2, 111.8, 60.9, 45.5, 38.1, 23.0, 21.2, 20.6. IR (film): ν 3056, 2983, 2923, 2861, 1611, 1495, 1416, 1362 cm⁻¹. MS: *m/z* (% relative intensity) 289(M⁺, 3), 275(20), 274(100), 153(29); HRMS: *m/z* calcd for C₂₁H₂₃N (M⁺) 289.1830, found 289.1828.

5-(4-Methoxyphenyl)-3a,7-dimethyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Dc):




3Dc

¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.28 (m, 2H), 6.93 (m, 3H), 6.77 (d, *J* = 1.5 Hz, 1H), 6.42 (d, *J* = 8.0 Hz, 1H), 5.61 (s, 1H), 3.86 (s, 3H), 3.44 (m, 2H), 2.16 (s, 3H), 2.02 (m, 4H), 1.11 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 158.8, 141.3, 135.3, 132.7, 130.3, 129.2, 127.8, 126.7, 124.4, 122.3, 113.5, 111.8, 60.9, 55.3, 45.4, 38.1, 23.0, 20.6. IR (film): ν 3056, 2969, 2855, 1603, 1509, 1362 cm⁻¹. MS: *m/z* (% relative intensity)


305(M⁺, 4), 291(18), 290(100), 275(9); HRMS: *m/z* calcd for C₂₁H₂₃NO (M⁺) 305.1780, found 305.1777.

7-Chloro-3a-methyl-5-*p*-tolyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Eb):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.22 (s, 4H), 7.05 (dd, *J* = 8.5, 2.4 Hz, 1H), 6.91 (d, *J* = 2.4 Hz, 1H), 6.39 (d, *J* = 8.5 Hz, 1H), 5.66 (s, 1H), 3.44 (m, 2H), 2.41 (s, 3H), 2.07 (m, 4H), 1.13 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 141.9, 137.2, 136.5, 135.0, 129.0, 128.9, 128.5, 128.3, 125.9, 123.5, 120.3, 112.7, 61.2, 45.5, 38.1, 23.5, 21.2, 20.4. IR (film): ν 3029, 2969, 2855, 1590, 1484, 1416 cm⁻¹. MS: *m/z* (% relative intensity) 309(M⁺, 4), 296(32), 295(19), 294(100); HRMS: *m/z* calcd for C₂₀H₂₀NCl (M⁺) 309.1284, found 309.1280.


7-Chloro-5-(4-methoxyphenyl)-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Ec):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.25 (m, 2H), 7.05 (dd, *J* = 8.5, 2.4 Hz, 1H), 6.92 (m, 3H), 6.38 (d, *J* = 8.5 Hz, 1H), 5.64 (s, 1H), 3.86 (s, 3H), 3.43 (m, 2H), 2.03 (m, 4H), 1.12 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 159.1, 141.9, 134.6, 131.8, 130.2, 128.4, 128.3, 125.8, 123.6, 120.3, 113.7, 112.7, 61.1, 55.3, 45.4, 38.1, 23.5, 20.5. IR


(film): ν 3064, 2963, 2842, 1603, 1509, 1476 cm^{-1} . MS: m/z (% relative intensity) 325(M^+ , 3), 312(30), 311(20), 310(100); HRMS: m/z calcd for $C_{20}\text{H}_{20}\text{NOCl}$ (M^+) 325.1233, found 325.1231.

5-Butyl-7-chloro-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Ej):



¹H NMR (CDCl_3 , TMS, 400 MHz): δ 7.07 (d, $J = 2.4$ Hz, 1H), 7.00 (dd, $J = 8.5, 2.4$ Hz, 1H), 6.28 (d, $J = 8.5$ Hz, 1H), 5.52 (s, 1H), 3.40 (m, 1H), 3.30 (m, 1H), 2.31 (m, 2H), 2.00 (m, 4H), 1.51 (m, 2H), 1.40 (m, 2H), 1.01 (s, 3H), 0.94 (t, $J = 7.3$ Hz, 3H). ¹³C NMR (CDCl_3 , TMS, 100 MHz): δ 141.9, 131.7, 127.8, 126.5, 123.3, 123.2, 120.2, 112.3, 60.9, 45.6, 38.2, 31.5, 30.4, 24.1, 22.6, 20.3, 14.0. IR (film): ν 2963, 2923, 2861, 1603, 1484, 1416, 1368 cm^{-1} . MS: m/z (% relative intensity) 275(M^+ , 5), 262(32), 261(17), 260(100); HRMS: m/z calcd for $C_{17}\text{H}_{22}\text{NCl}$ (M^+) 275.1441, found 275.1440.


9-Fluoro-5-(4-methoxyphenyl)-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-a]quinoline (3Fc):



¹H NMR (CDCl_3 , TMS, 300 MHz): δ 7.24 (d, $J = 8.2$ Hz, 2H), 6.90 (d, $J = 8.4$ Hz, 2H), 6.82 (m, 2H), 6.56 (m, 1H), 5.53 (s, 1H), 3.96 (m, 1H), 3.83 (s, 3H), 3.45 (m, 1H), 1.97 (m, 3H), 1.79 (m, 1H), 1.19 (s, 3H). ¹³C NMR (CDCl_3 , TMS, 75 MHz): δ 159.0, 155.2,


152.0, 134.6 (d, $J_{\text{CF}} = 3.4$ Hz), 132.3, 130.3, 129.6, 126.6 (d, $J_{\text{CF}} = 4.7$ Hz), 121.8 (d, $J_{\text{CF}} = 2.6$ Hz), 117.3 (d, $J_{\text{CF}} = 7.7$ Hz), 115.0 (d, $J_{\text{CF}} = 20.4$ Hz), 113.5, 61.0, 55.3, 52.6 (d, $J_{\text{CF}} = 7.5$ Hz), 39.8, 27.3, 23.4 (d, $J_{\text{CF}} = 1.1$ Hz). IR (film): ν 2969, 1603, 1503, 1462, 1349 cm^{-1} . ESI, MS: m/e 310 ([M+H] $^+$); HRMS: m/z calcd for $\text{C}_{20}\text{H}_{20}\text{FNO} (\text{M}^+)$ 309.1529, found 309.1536.

3a-Methyl-5-*p*-tolyl-1,2,3,3a-tetrahydrobenzo[*h*]pyrrolo[1,2-a]quinoline (3Gb):



^1H NMR (CDCl_3 , TMS, 400 MHz): δ 8.28 (d, $J = 8.1$ Hz, 1H), 7.77 (d, $J = 8.1$ Hz, 1H), 7.35 (m, 8H), 5.55 (s, 1H), 4.03 (m, 1H), 3.34 (m, 1H), 2.43 (s, 3H), 2.16 (m, 2H), 2.00 (m, 1H), 1.77 (m, 1H), 1.25 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 142.0, 137.8, 137.3, 137.1, 134.5, 130.1, 129.5, 129.3, 128.4, 127.6, 125.9, 125.4, 125.3, 124.9, 122.7, 121.2, 61.6, 57.6, 41.6, 27.0, 26.6, 21.6. IR (film): ν 2975, 2926, 2871, 1512, 1381 cm^{-1} . MS: m/z (% relative intensity) 325(M $^+$, 5), 311(20), 310(100), 153(58); HRMS: m/z calcd for $\text{C}_{24}\text{H}_{23}\text{N} (\text{M}^+)$ 325.1830, found 325.1825.

5-(4-Methoxyphenyl)-3a-methyl-1,2,3,3a-tetrahydrobenzo[*h*]pyrrolo[1,2-a]quinoline (3Gc):




^1H NMR (CDCl_3 , TMS, 300 MHz): δ 8.28 (d, $J = 8.1$ Hz, 1H), 7.74 (d, $J = 8.1$ Hz, 1H),

7.34 (m, 6H), 6.93 (d, $J = 8.7$ Hz, 2H), 5.50 (s, 1H), 3.99 (m, 1H), 3.84 (s, 3H), 3.31 (m, 1H), 2.13 (m, 2H), 1.97 (m, 1H), 1.74 (m, 1H), 1.21 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 158.9, 141.6, 136.3, 134.0, 132.7, 130.3, 129.8, 129.4, 128.0, 125.5, 125.0, 124.9, 124.4, 122.3, 120.8, 113.6, 61.1, 57.1, 55.3, 41.2, 26.6, 26.2. IR (film): ν 2963, 2861, 1603, 1509, 1422, 1389 cm^{-1} . MS: m/z (% relative intensity) 341(M^+ , 5), 327(23), 326(100), 282(12); HRMS: m/z calcd for $\text{C}_{24}\text{H}_{23}\text{NO} (\text{M}^+)$ 341.1780, found 341.1778.

7'-Methoxy-3a'-methyl-5'-*p*-tolyl-3',3a'-dihydro-1'H-spiro[cyclohexane-1,2'-


pyrrolo[1,2-a]quinoline] (3Hb):



^1H NMR (CDCl_3 , TMS, 300 MHz): δ 7.25 (d, $J = 7.5$ Hz, 2H), 7.19 (d, $J = 8.0$ Hz, 2H), 6.76 (dd, $J = 8.5, 2.9$ Hz, 1H), 6.64 (d, $J = 2.8$ Hz, 1H), 6.50 (d, $J = 8.6$ Hz, 1H), 5.68 (s, 1H), 3.67 (s, 3H), 3.27 (dd, $J = 40.9, 9.6$ Hz, 2H), 2.42 (s, 3H), 1.92 (dd, $J = 48.2, 12.5$ Hz, 2H), 1.55 (m, 10H), 1.12 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 150.9, 138.4, 137.1, 136.8, 134.8, 130.9, 129.0, 128.8, 123.7, 114.1, 113.6, 112.7, 60.7, 58.8, 55.9, 52.1, 40.3, 38.8, 38.7, 25.8, 24.0, 23.7, 21.2. IR (film): ν 3056, 2988, 2923, 2861, 1603, 1489, 1416 cm^{-1} . MS: m/z (% relative intensity) 373(M^+ , 2), 359(26), 358(100); HRMS: m/z calcd for $\text{C}_{26}\text{H}_{31}\text{NO} (\text{M}^+)$ 373.2406, found 373.2389.

7'-Methoxy-5'-(4-methoxyphenyl)-3a'-methyl-3',3a'-dihydro-1'H-spiro[cyclohexane-


1,2'-pyrrolo[1,2-a]quinoline] (3Hc):



3Hc

¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.27 (m, 2H), 6.90 (m, 2H), 6.75 (dd, J = 8.6, 2.9 Hz, 1H), 6.62 (d, J = 2.8 Hz, 1H), 6.48 (d, J = 8.6 Hz, 1H), 5.65 (s, 1H), 3.85 (s, 3H), 3.67 (s, 3H), 3.26 (dd, J = 41.9, 9.6 Hz, 2H), 1.91 (dd, J = 48.3, 12.5 Hz, 2H), 1.54 (m, 10H), 1.10 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 158.9, 150.9, 138.4, 134.4, 132.4, 130.7, 130.2, 123.8, 114.0, 113.6, 113.5, 112.6, 60.7, 58.7, 55.9, 55.3, 52.1, 40.3, 38.8, 38.7, 25.8, 24.0, 23.9, 23.7. IR (film): ν 3056, 2929, 2855, 1603, 1509, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 375(23), 374(100), 153(30), 136(28); HRMS: *m/z* calcd for C₂₆H₃₁NO₂(M⁺) 389.2355, found 389.2348.

3a'-Methyl-7'-phenoxy-5'-*p*-tolyl-3',3a'-dihydro-1'H-spiro[cyclohexane-1,2'-pyrrolo[1,2-a]quinoline] (3Ib):




3Ib

¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.19 (m, 6H), 6.89 (m, 4H), 6.78 (d, J = 2.5 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 5.67 (s, 1H), 3.31 (dd, J = 49.6, 9.7 Hz, 2H), 2.35 (s, 3H),


1.94 (dd, $J = 48.3, 12.6$ Hz, 2H), 1.55 (m, 10H), 1.16 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 159.4, 145.8, 140.6, 136.9, 136.8, 134.7, 130.4, 129.3, 128.9, 128.8, 123.6, 121.5, 120.6, 118.8, 116.5, 113.1, 60.9, 58.3, 52.1, 40.2, 38.9, 38.7, 25.8, 24.2, 24.0, 23.7, 21.1. IR (film): ν 2929, 2855, 1597, 1484, 1416 cm^{-1} . MS: m/z (% relative intensity) 435(M^+ , 3), 422(31), 421(100), 153(17); HRMS: m/z calcd for $\text{C}_{31}\text{H}_{33}\text{NO} (\text{M}^+)$ 435.2562, found 435.2541.

5'-(4-Methoxyphenyl)-3a'-methyl-7'-phenoxy-3',3a'-dihydro-1'H-spiro[cyclohexane-1,2'-pyrrolo[1,2-a]quinoline] (3Ic):



^1H NMR (CDCl_3 , TMS, 300 MHz): δ 7.25 (m, 4H), 6.92 (m, 6H), 6.78 (d, $J = 2.4$ Hz, 1H), 6.50 (d, $J = 8.5$ Hz, 1H), 5.66 (s, 1H), 3.82 (s, 3H), 3.32 (dd, $J = 50.5, 9.7$ Hz, 2H), 1.95 (dd, $J = 48.5, 12.6$ Hz, 2H), 1.56 (m, 10H), 1.17 (s, 3H). ^{13}C NMR (CDCl_3 , TMS, 75 MHz): δ 159.4, 159.0, 145.9, 140.6, 134.3, 132.1, 130.2, 130.1, 129.4, 123.8, 121.5, 120.6, 118.8, 116.6, 113.6, 113.1, 60.9, 58.3, 55.3, 52.1, 40.2, 38.9, 38.7, 25.8, 24.1, 24.0, 23.7. IR (film): ν 2934, 2850, 1596, 1507, 1486 cm^{-1} . MS: m/z (% relative intensity) 437(23), 281(22), 199(14), 198(100); HRMS: m/z calcd for $\text{C}_{31}\text{H}_{33}\text{NO}_2 (\text{M}^+)$ 451.2511, found 451.2499.


1-(4-Methoxyphenyl)-2-methyl-2-(phenylethynyl)piperidine (5Ja):



5Ja

¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.47 (m, 2H), 7.34 (m, 5H), 6.83 (dd, J = 12.3, 3.3 Hz, 2H), 3.80 (s, 3H), 3.42 (m, 1H), 2.85 (d, J = 11.6 Hz, 1H), 1.89 (m, 2H), 1.69 (m, 4H), 1.28 (s, 3H). ¹³C NMR (CDCl₃, TMS, 100 MHz): δ 157.0, 143.7, 131.6, 128.4, 128.2, 127.7, 123.7, 113.2, 91.6, 86.1, 56.1, 55.3, 51.6, 41.1, 29.7, 26.8, 22.2. IR (film): ν 3002, 2942, 1603, 1509, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 305(M⁺, 44), 291(21), 290(100), 136(68); HRMS: *m/z* calcd for C₂₁H₂₃NO (M⁺) 305.1780, found 305.1782.


1-(4-Methoxyphenyl)-2-((4-methoxyphenyl)ethynyl)-2-methylpiperidine (5Jc):



5Jc


¹H NMR (CDCl₃, TMS, 400 MHz): δ 7.38 (dd, J = 6.8, 2.1 Hz, 2H), 7.31 (dd, J = 7.0, 2.1 Hz, 2H), 6.83 (m, 4H), 3.81 (s, 3H), 3.78 (s, 3H), 3.40 (m, 1H), 2.82 (d, J = 13.2 Hz, 1H), 1.90 (m, 2H), 1.68 (m, 4H), 1.25 (s, 3H). ¹³C NMR (CDCl₃, TMS, 100 MHz): δ 159.2, 157.0, 143.8, 132.9, 128.4, 115.9, 113.9, 113.2, 89.9, 85.9, 56.1, 55.3, 55.2, 51.6, 41.1, 29.8, 26.8, 22.2. IR (film): ν 3056, 2936, 1603, 1503, 1416 cm⁻¹. MS: *m/z* (% relative intensity) 335(M⁺, 87), 334(23), 320(100), 153(74); HRMS: *m/z* calcd for C₂₂H₂₅NO₂ (M⁺) 335.1885, found 335.1878.

2-((4-Fluorophenyl)ethynyl)-1-(4-methoxyphenyl)-2-methylpiperidine (5Jh):




¹H NMR (CDCl₃, TMS, 400 MHz): δ 7.44 (m, 2H), 7.31 (m, 2H), 7.02 (m, 2H), 6.83 (m, 2H), 3.80 (s, 3H), 3.40 (m, 1H), 2.85 (m, 1H), 1.90 (m, 2H), 1.68 (m, 4H), 1.27 (s, 3H).
¹³C NMR (CDCl₃, TMS, 100 MHz): δ 163.4, 160.9, 157.0, 143.7, 133.3 (d, $J_{CF} = 8.2$ Hz), 128.4, 119.7 (d, $J_{CF} = 3.4$ Hz), 115.4 (d, $J_{CF} = 21.8$ Hz), 113.2, 91.2, 85.0, 56.1, 55.3, 51.5, 41.0, 29.7, 26.7, 22.2. IR (film): ν 2990, 2940, 1603, 1507, 1422 cm⁻¹. MS: *m/z* (%) relative intensity) 323(M⁺, 51), 322(27), 309(23), 308(100); HRMS: *m/z* calcd for C₂₁H₂₂NOF (M⁺) 323.1685, found 323.1676.

1-Benzyl-2-methyl-2-(phenylethyynyl)pyrrolidine (5Ka):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.49 (m, 2H), 7.36 (m, 8H), 4.03 (d, $J = 13.1$ Hz, 1H), 3.41 (d, $J = 13.1$ Hz, 1H), 2.93 (m, 1H), 2.51 (m, 1H), 2.25 (m, 1H), 1.86 (m, 3H), 1.55 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 140.3, 131.7, 128.8, 128.2, 128.1, 127.8, 126.7, 123.6, 91.0, 84.7, 60.2, 54.8, 51.7, 40.6, 26.1, 20.5. IR (film): ν 2975, 2940, 1603, 1485, 1422 cm⁻¹. MS: *m/z* (%) relative intensity) 275(M⁺, 2), 261(20), 260(100); HRMS: *m/z* calcd for C₂₀H₂₁N (M⁺) 275.1674, found 275.1663.

1-Benzyl-2-((4-methoxyphenyl)ethynyl)-2-methylpyrrolidine (5Kc):



¹H NMR (CDCl₃, TMS, 400 MHz): δ 7.41 (m, 4H), 7.33 (m, 2H), 7.26 (m, 1H), 6.87 (m, 2H), 4.01 (d, *J* = 13.1 Hz, 1H), 3.84 (s, 3H), 3.40 (d, *J* = 13.1 Hz, 1H), 2.93 (m, 1H), 2.50 (m, 1H), 2.23 (m, 1H), 1.85 (m, 3H), 1.54 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 159.2, 140.4, 133.1, 128.8, 128.2, 126.7, 115.8, 113.9, 89.4, 84.4, 60.2, 55.3, 54.8, 51.7, 40.6, 26.1, 20.5. IR (film): ν 3064, 2977, 2936, 2834, 1603, 1503, 1416 cm⁻¹. MS: *m/z* (% relative intensity) 305(M⁺, 3), 291(21), 290(100); HRMS: *m/z* calcd for C₂₁H₂₃NO (M⁺) 305.1780, found 305.1765.

1-Benzyl-2-((4-fluorophenyl)ethynyl)-2-methylpyrrolidine (5Kh):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.36 (m, 7H), 7.02 (m, 2H), 4.01 (d, *J* = 13.1 Hz, 1H), 3.38 (d, *J* = 13.1 Hz, 1H), 2.91 (m, 1H), 2.48 (m, 1H), 2.21 (m, 1H), 1.85 (m, 3H), 1.53 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 163.9, 160.6, 140.2, 133.5 (d, *J*_{CF} = 8.1 Hz), 128.8, 128.3, 126.7, 119.6 (d, *J*_{CF} = 3.5 Hz), 115.4 (d, *J*_{CF} = 21.8 Hz), 90.6, 83.6, 60.2, 54.7, 51.7, 40.6, 26.0, 20.5. IR (film): ν 2975, 2940, 2815, 1597, 1499 cm⁻¹. MS: *m/z* (% relative intensity) 293(M⁺, 3), 279(19), 278(100); HRMS: *m/z* calcd for C₂₀H₂₀NF (M⁺) 293.1580, found 293.1573.

Procedure for the Au[P(*t*-Bu)₂(*o*-biphenyl)]Cl/AgSbF₆-Catalyzed Reaction of 4-

Methoxy-*N*-(pent-4-ynyl)aniline (1A). A mixture of Au[P(*t*-Bu)₂(*o*-biphenyl)]Cl (0.01 mmol), AgSbF₆ (0.01 mmol) and 4-methoxy-*N*-(pent-4-ynyl)aniline (0.2 mmol) in CH₃CN (1.0 mL) was stirred at 80 °C for 36 h under Ar atmosphere. Solvent was removed under reduced pressure, and the residue was purified by a silica gel column chromatography (EtOAc/Hx, 1:15) to give the product **4** in 43% yield.

4-Methoxy-*N*-(3-(7-methoxy-3a-methyl-1,2,3,3a-tetrahydropyrrolo[1,2-*a*]quinolin-5-yl)propyl)aniline (4):



¹H NMR (CDCl₃, TMS, 300 MHz): δ 6.74 (m, 4H), 6.56 (dd, *J* = 10.0, 3.3 Hz, 2H), 6.37 (d, *J* = 8.5 Hz, 1H), 5.57 (s, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 3.35 (m, 2H), 3.14 (t, *J* = 6.9 Hz, 2H), 2.49 (m, 2H), 1.91 (m, 6H), 0.99 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 152.0, 150.8, 142.7, 138.2, 131.5, 127.6, 122.9, 114.9, 114.0, 113.5, 112.5, 110.6, 60.6, 56.0, 55.8, 46.1, 44.7, 38.2, 29.7, 28.2, 23.2, 20.6. IR (film): ν 2961, 2836, 1506, 1422 cm⁻¹. MS: *m/z* (% relative intensity) 378(M⁺, 13), 364(24), 363(100), 240(38); HRMS: *m/z* calcd for C₂₄H₃₀N₂O₂ (M⁺) 378.2307, found 378.2303.

Gram-Scale Catalytic Synthesis of 7-Methoxy-3a-methyl-5-phenyl-1,2,3,3a-tetrahydropyrrolo[1,2-*a*]quinoline (3Aa) Using Gold(I) Complexes. A mixture of

$\text{Au}[\text{P}(t\text{-Bu})_2(o\text{-biphenyl})]\text{Cl}$ (0.125 mmol), AgSbF_6 (0.125 mmol), phenylacetylene (20 mmol) and 4-methoxy-*N*-(pent-4-ynyl)aniline (5 mmol) in water (2 mL) was stirred at 75 °C under Ar atmosphere. After stirring for 26 h, $\text{Au}[\text{P}(t\text{-Bu})_2(o\text{-biphenyl})]\text{Cl}$ (0.125 mmol) and AgSbF_6 (0.125 mmol) were added to this mixture, and the resulting mixture was stirred for 30 h at the same temperature. Water was removed under reduced pressure. The residue was purified by vacuum distillation at 120-140 °C to give the product **3Aa** (1.3 g) in 91% yield.


A mixture of $\text{Au}[\text{P}(t\text{-Bu})_2(o\text{-biphenyl})]\text{Cl}$ (0.33 mmol), AgSbF_6 (0.33 mmol), phenylacetylene (66 mmol) and 4-methoxy-*N*-(pent-4-ynyl)aniline (22 mmol) in water (2 mL) was stirred at 75 °C under Ar atmosphere. After stirring for 48 h, $\text{Au}[\text{P}(t\text{-Bu})_2(o\text{-biphenyl})]\text{Cl}$ (0.22 mmol) and AgSbF_6 (0.22 mmol) were added to this mixture and the resulting mixture was stirred for 60 h at the same temperature. Water was removed under reduced pressure, and the residue was purified by flash chromatography to give the product **3Aa** (5.5 g) in 91% yield.

Procedure for the $\text{Au}[\text{P}(t\text{-Bu})_2(o\text{-biphenyl})]\text{Cl}/\text{AgSbF}_6$ -Catalyzed Reaction of 4-Methoxy-*N*-(pent-4-ynyl)aniline with Phenylacetylene at Room Temperature.

To a mixture of $\text{Au}[\text{P}(t\text{-Bu})_2(o\text{-biphenyl})]\text{Cl}$ (0.01 mmol) and AgSbF_6 (0.01 mmol) in H_2O (1.0 mL) was added 4-methoxy-*N*-(pent-4-ynyl)aniline (0.2 mmol) with stirring. The reaction mixture was capped and stirred for 10 min at room temperature. *N*-(4-methoxyphenyl)-5-aminopentan-2-one^[S6] was obtained in 86% yield.


To a mixture of $\text{Au}[\text{P}(t\text{-Bu})_2(o\text{-biphenyl})]\text{Cl}$ (0.01 mmol) and AgSbF_6 (0.01 mmol) in H_2O (1.0 mL) was added *N*-(4-methoxyphenyl)-5-aminopentan-2-one (0.2 mmol) and

phenylacetylene (0.8 mmol) with stirring. The reaction mixture was capped and stirred for 24 h at room temperature. Solvent was removed under reduced pressure, and the residue was purified by a silica gel column chromatography (EtOAc/Hx, 1:100) to give the product **6** in 73% yield.



To a mixture of $\text{Au}[\text{P}(t\text{-Bu})_2(\text{o-biphenyl})]\text{Cl}$ (0.01 mmol) and AgSbF_6 (0.01 mmol) in H_2O (1.0 mL) was added 4-methoxy-*N*-(pent-4-ynyl)aniline (0.2 mmol) and phenylacetylene (0.8 mmol) with stirring. The reaction mixture was capped and stirred for 24 h at room temperature. Solvent was removed under reduced pressure. The residue was purified by a silica gel column chromatography (EtOAc/Hx, 1:100) to give the product **6** in 74% yield.

1-(4-Methoxyphenyl)-2-methyl-2-(phenylethyynyl)pyrrolidine (6):




¹H NMR (CDCl₃, TMS, 300 MHz): δ 7.39 (m, 2H), 7.28 (m, 3H), 7.05 (m, 2H), 6.88 (m, 2H), 3.78 (s, 3H), 3.45 (m, 2H), 2.50 (m, 1H), 2.09 (m, 3H), 1.65 (s, 3H). ¹³C NMR (CDCl₃, TMS, 75 MHz): δ 152.0, 140.4, 131.6, 128.1, 127.8, 123.4, 116.9, 114.2, 93.2, 83.3, 57.6, 55.7, 50.5, 44.0, 26.2, 22.5. IR (film): ν 2969, 2948, 2844, 1507, 1485 cm⁻¹. MS: *m/z* (% relative intensity) 291(M⁺, 18), 276(75), 153(38), 149(100); HRMS: *m/z* calcd for C₂₀H₂₁NO (M⁺) 291.1623, found 291.1617.


Procedure for the Conversion of 1-(4-Methoxyphenyl)-2-methyl-2-(phenylethyynyl)pyrrolidine (6) to 3Aa Catalyzed by Au[P(*t*-Bu)₂(*o*-biphenyl)]Cl/AgSbF₆. To a mixture of Au[P(*t*-Bu)₂(*o*-biphenyl)]Cl (0.005 mmol) and AgSbF₆ (0.005 mmol) in H₂O (0.5 mL) was added **6** (0.1 mmol) with stirring. The reaction mixture was capped and stirred for 8 h at 60 °C. Solvent was removed under reduced pressure, and the residue was purified by a silica gel column chromatography (EtOAc/Hx, 1:100) to give the product **3Aa** in 96% yield.

Procedure for the Isotope Studies. Deuterated amionalkyne **1L-d₂** was prepared by deprotonation of **1A** using *n*BuLi (2.2 equiv) at -78 °C followed by quenching with D₂O in 76% yield with >98% deuterium incorporation at both terminal alkynyl and amino sites. A mixture of Au[P(*t*-Bu)₂(*o*-biphenyl)]Cl (0.005 mmol), AgSbF₆ (0.005 mmol), phenylacetylene-*d* (0.4 mmol) and amionalkyne **1L-d₂** (0.1 mmol) in D₂O (0.4 mL) was stirred at 75 °C for 24 h under Ar atmosphere. D₂O was removed under reduced pressure, and the residue was purified by a silica gel column chromatography (EtOAc/Hx, 1:100) to give the product **3Lk** in 85% yield, which was analyzed using ¹H NMR spectroscopy to determine the content of the deuterium incorporation. ¹H NMR (CDCl₃, TMS, 300

MHz): δ 7.34 (m, 5H), 6.74 (dd, J = 8.6, 2.9 Hz, 1H), 6.58 (d, J = 2.9 Hz, 1H), 6.44 (d, J = 8.6 Hz, 1H), 3.64 (s, 3H), 3.40 (m, 2H), 2.02 (t, J = 6.9 Hz, 2H).



A mixture of $\text{Au}[\text{P}(t\text{-Bu})_2(\text{o-biphenyl})]\text{Cl}$ (0.005 mmol), AgSbF_6 (0.005 mmol), phenylacetylene (0.4 mmol) and amionalkyne **1A** (0.1 mmol) in D_2O (0.4 mL) were stirred at 75 °C for 24 h under Ar atmosphere. D_2O was removed under reduced pressure, and the residue was purified by a silica gel column chromatography (EtOAc/Hx , 1:100) to give the product **7** in 89% yield, which was analyzed using ^1H NMR spectroscopy to determine the content of the deuterium incorporation. ^1H NMR (CDCl_3 , TMS, 300 MHz): δ 7.34 (m, 5H), 6.74 (dd, J = 8.6, 2.9 Hz, 1H), 6.58 (d, J = 2.9 Hz, 1H), 6.44 (d, J = 8.6 Hz, 1H), 3.64 (s, 3H), 3.40 (m, 2H), 2.02 (t, J = 6.9 Hz, 2H), 1.00 (m, 0.4H).



Cytotoxicity Studies (MTT Assay)

Cervical epithelioid carcinoma (HeLa) cell line and normal lung fibroblast (CCD-19Lu) cell line were maintained in a minimum essential medium with Earle's balanced salts (MEM), respectively. The medium for HeLa was supplemented with 2 mM *L*-glutamine, 1% sodium pyruvate, and 10% fetal bovine serum; and the medium for CCD-19Lu was supplemented with 2 mM *L*-glutamine and 10% fetal bovine serum. Penicillin (100 U/mL) and Streptomycin (100 µg/mL) were added to all media. Cultures were incubated at 37 °C in a 5% CO₂/95% air humidified atmosphere.


Assays on the cytotoxic effects were conducted in 96-well flat-bottomed microtitre plates. The supplemented culture medium (100 µL) with cells (6×10^4 cells/mL) was added into each well and was incubated (37 °C, 5% CO₂/95% air) for 24 h. All the media were then removed and fresh supplemented medium (100 µL) was added into each well. Compound **3Bc** dissolved in the culture medium (100 µL + < 1 % DMSO) was added into a set of wells. After mixing, the sample-containing media (100 µL) were drawn and added to another set of wells. Such processes were repeated to provide a set of two-fold dilution series. Controlled wells only contained 100 µL of supplemented media. Microtitre plates were incubated at 37 °C in a 5% CO₂/95% air humidified atmosphere for further 3 days. All the cytotoxicity assays were run in parallel with a negative control (i.e., untreated population). Assessment of the cytotoxicity was carried out using a modified method of Mosmann based 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay [T. Mosmann, *J. Immunol. Methods* **1983**, *65*, 55–63.]. At the end of each incubation period, 10 µL of the MTT solution (Cell Proliferation Kit I, Roche) were added into each well and the cultures were further incubated for 4 h at 37 °C in a 5%

CO₂/95% air humidified atmosphere. Then 100 μ L of the solubilization solution was added into the wells to lyse the cells and solubilize the formazan complex formed. The microtitre plates were maintained in a dark and humidified chamber overnight. The formation of formazan was measured with a microtitre plate reader at 550 nm, and the percentages of cell survival were determined. The cytotoxicity was evaluated based on the percentage cell survival in a dosedependence manner relative to the negative control.

References:

- [S1] A. K. Al-Sa'Ady, C. A. McAuliffe, R. V. Parish, J. A. Sandeank, *Inorg. Synth.* **1985**, 191.
- [S2] P. de Frémont, N. M. Scott, E. D. Stevens, S. P. Nolan, *Organometallics* **2005**, *24*, 2411.
- [S3] C. Nieto-Oberhuber, S. López, A. M. Echavarren, *J. Am. Chem. Soc.* **2005**, *127*, 6178.
- [S4] S. Serna, I. Tellitu, E. Domínguez, I. Moreno, R. SanMartín, *Org. Lett.* **2005**, *7*, 3073.
- [S5] S. Chang, M. Lee, D. Y. Jung, E. J. Yoo, S. H. Cho, S. K. Han, *J. Am. Chem. Soc.* **2006**, *128*, 12366.
- [S6] A. J. Duplantier, C. J. Andresen, J. B. Cheng, V. L. Cohan, C. Decker, F. M. DiCapua, K. G. Kraus, K. L. Johnson, C. R. Turner, J. P. UmLand, J. W. Watson, R. T. Wester, A. S. Williams, J. A. Williams, *J. Med. Chem.* **1998**, *41*, 2268.


Table S1. Effect of catalyst, solvent and temperature on tandem synthesis of pyrrolo[1,2- α]quinoline **3Aa**.^[a]



Entry	Catalyst	Solvent	Temperature [°C]	Time [h]	Yield of 3Aa [%] ^[b]	Yield of 4 [%] ^[b]	Yield of 6 [%] ^[b]
1	AgSbF ₆	CH ₃ NO ₂	60	24	0	0	0
2	AuCl ₃	CH ₃ NO ₂	60	24	0	0	0
3	AuCl/AgSbF ₆	CH ₃ NO ₂	60	24	3	12	0
4	(IPr)AuCl ^[c] /AgSbF ₆	CH ₃ NO ₂	60	24	0	0	0
5	Ph ₃ PAuCl/AgSbF ₆	CH ₃ NO ₂	60	24	3	12	0
6	Au[P(<i>t</i> -Bu) ₂ (<i>o</i> -biphenyl)]Cl/AgSbF ₆	CH ₃ NO ₂	60	24	36	14	0
7	Au[P(<i>t</i> -Bu) ₂ (<i>o</i> -biphenyl)]Cl/AgBF ₄	CH ₃ NO ₂	60	24	0	0	0
8	Au[P(<i>t</i> -Bu) ₂ (<i>o</i> -biphenyl)]Cl/AgPF ₆	CH ₃ NO ₂	60	24	6	0	0
9	Au[P(<i>t</i> -Bu) ₂ (<i>o</i> -biphenyl)]Cl/AgOTf	CH ₃ NO ₂	60	24	0	0	0
10 ^[d]	CF ₃ SO ₃ H	H ₂ O	75	26	0	0	0
11 ^[d]	AgSbF ₆	H ₂ O	75	26	0	0	0
12 ^[d]	AuCl	H ₂ O	75	26	30	0	60
13 ^[d]	Au[P(Cy) ₂ (2',4',6'-triisopropyl- <i>o</i> -biphenyl)]Cl/AgSbF ₆	H ₂ O	75	26	13	0	74
14 ^[d]	Au[P(<i>t</i> -Bu) ₂ (2',4',6'-triisopropyl- <i>o</i> -biphenyl)]Cl/AgSbF ₆	H ₂ O	75	26	53	0	26

[a] Reaction conditions: **1A/2a/catalyst** = 1:2:0.05. [b] Determined by ¹H NMR with 0.005 mol of trimethyl(phenyl)silane as an internal standard. [c] IPr = *N,N'*-bis(2,6-diisopropylphenyl)-imidazol-2-ylidene. [d] Reaction conditions: **1A/2a/catalyst** = 1:4:0.05.

Scheme S1. Reactions of 1,5-aminoalkyne **1J** and *N*-benzylpent-4-yn-1-amine (**1K**) with alkynes **2a**, **2c**, and **2h** catalyzed by AuCl.



Scheme S2.





Figure S1. ESI MS spectrum of a solution of **6** and Au[P(*t*-Bu)₂(*o*-biphenyl)]SbF₆ (20 mol%) in CH₃CN (spectrum **a**) showing a cluster peak at *m/z* 786 which can be attributed to the adduct formed between Au⁺[P(*t*-Bu)₂(*o*-biphenyl)]) and **6**. The observed isotopic distribution well matches the calculated one (spectrum **b**)

Spectrum a



Spectrum b

Isotopic Distribution Calculator: Elemental C₄₀H₄₈Au₁N₁O₁P₁

